Processa Pharmaceuticals, Inc. Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Processa Pharmaceuticals, Inc. stock issued during period, value, restricted stock award, net of forfeitures for the quarter ending 2023-09-30 was $142.89K.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures 3 month | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures 12 month |
|---|---|---|
| 2023-09-30 | $142.89K 10-Q · filed 2024-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |